Oneview Healthcare PLC

Total reported revenue fell 14% year over year in H1 2026, though management said it was down only 9% on a constant-currency basis. Recurring revenue increased 13% year over year, or 20% constant currency, while nonrecurring revenue declined by EUR 1.3 million. Gross margin rose to 70% from 61%, and gross profit was stable at EUR 3.8 million. Operating EBITDA loss improved 11% year over year to EUR 4 million, and operating cash outflow declined 15%. Cash at June 30 was EUR 7.2 million, with pro forma cash of EUR 11.4 million including the second tranche of the $19 million placement. Management did not provide formal next-quarter or full-year financial guidance, but said recurring revenue growth, Bedside Hub, and new logos are the main second-half priorities, and Darragh Lyons said the company is focused on reaching cash flow breakeven in the near term and expects further efficiency gains in H2.

James Fitter framed the half as a period of progress toward scalable growth, emphasizing the shift toward recurring revenue, the new Bedside Hub channel, and the rebuild of the product front end. He was upbeat about Epic and Baxter as distribution channels, saying the company is getting 'unparalleled access' to the market and that Bedside Hub should shorten sales and deployment cycles. His tone was confident and promotional, but he also acknowledged pressure in Australia and some procurement delays tied to Bedside Hub interest.

Darragh Lyons focused on margin improvement, cost discipline, and balance-sheet strength. He said cash operating expenses were 6% lower year over year, gross margin rose to 70% from 61%, operating EBITDA loss was EUR 4 million, and pro forma cash was EUR 11.4 million after including the second tranche of the March placement. He said the company is focused on cash flow breakeven, that spend has reduced by 10% since its peak in H2 2024, and that further efficiencies should come in H2, though he also noted there is a limit to how far costs can be cut without relying more on revenue scaling.

Analysts asked whether Oneview could bring the Epic solution to Australia to compete with cheaper undercut bids; management said New South Wales Health is moving toward Epic and that the solution could fit Australian Epic rollouts in 2027. Questions also focused on AI’s impact on development expense and cash flow breakeven; management said AI has improved development speed, quality, and pricing power, and that Bedside Hub should shorten sales cycles and lower deployment friction. On the USD 50 billion rural health program, management said it is too early to quantify the benefit but that Oneview and Baxter are exploring packages that could work, especially for smaller hospitals. In response to cost-cutting questions, Darragh said more efficiencies are possible, but eventually revenue growth has to leverage the existing cost base.